Mitigation and management strategies for ocular events associated with tisotumab vedotin. Kim SK, Ursell P, Coleman RL, Monk BJ, et al. Gynecol Oncol 2022;165:385-392.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kim SK, Ursell P, Coleman RL, Monk BJ, et al. Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol 2022;165:385-392.
PMID: 35277279